Back to top

Image: Shutterstock

Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now

Read MoreHide Full Article

Key Takeaways

  • NeuroPace's RNS expansion and new indications support long-term growth despite recent revenue weakness.
  • NPCE cut its 2026 revenue outlook to $91-$92M as third-quarter RNS sales rose just 1.4% year over year.
  • Potential IGE and adolescent approvals, Remote Care and higher reimbursement could drive future RNS growth.

NeuroPace, Inc. (NPCE - Free Report) is well-positioned for long-term growth, driven by expanding RNS adoption, broader referral networks, improved reimbursement and potential IGE and adolescent indication expansions. Remote Care and AI-enabled innovations offer additional growth opportunities. However, near-term growth may be constrained by commercial execution challenges, weak performance and regulatory and adoption uncertainties surrounding new indications.

In the year-to-date period, this Zacks Rank #3 (Hold) company’s shares have declined 46.7%, significantly underperforming the industry’s 1.4% growth and the S&P 500’s 6.1% rise.

As a developer of neuromodulation technology for epilepsy, NeuroPace’s core product is the RNS System, a closed-loop, brain-responsive implant that monitors intracranial EEG, detects patient-specific abnormal electrical patterns and delivers targeted stimulation to help prevent seizures. It has a market capitalization of $282.5 million.

The company projects 59.5% growth for 2027 and expects to maintain its strong performance going forward. NeuroPace’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 32.4%.

Zacks Investment Research
Image Source: Zacks Investment Research

Factors Favoring NPCE’s Growth

Expanding Physician Adoption and Commercial Reach: NeuroPace continues to see strong physician interest in RNS therapy, reaching a new high in active prescribers in the third quarter of 2026. The company is making progress in expanding its medium-sized accounts and generating patient referrals from community centers and Level 3 programs. Management is strengthening commercial coverage, improving patient pipeline visibility and investing in additional quota-carrying sales representatives to improve account productivity. These efforts, along with the expected recovery in larger accounts, could support a return to stronger RNS growth. Management expects RNS revenue growth of approximately 15% in 2027, accelerating toward 20% by year-end.

Potential IGE and Pediatric Indication Expansions: NeuroPace is advancing clinical and regulatory initiatives to expand RNS therapy into drug-resistant idiopathic generalized epilepsy (IGE) and adolescent focal epilepsy. Following its FDA Submission Issue Request meeting, the company expects to submit an amendment to its IGE PMA supplement around year-end 2026, with potential approval by mid-2027. The 24-month NAUTILUS results demonstrated a 100% median reduction in generalized tonic-clonic seizures. NeuroPace initiated enrollment in the AURORA real-world evidence study to support a potential expansion into patients aged 12-17 years. Management estimates this population represents approximately 70,000 patients and a potential $3.5 billion market opportunity. These expansions could substantially broaden the addressable market for RNS.

Remote Care and Reimbursement Improvements: NeuroPace submitted its Remote Care PMA supplement to the FDA during the third quarter, ahead of its previously communicated timeline. The technology is designed to enable physicians to program the RNS System through telehealth, reducing the need for certain in-person visits and addressing travel-related barriers for patients living far from epilepsy centers. Management sees potential FDA approval in the second quarter of 2027. The final 2027 CMS OPPS rule increases hospital outpatient reimbursement for the APC covering RNS replacement procedures by approximately 11%. These developments could improve patient access, support physician flexibility and provide a reimbursement tailwind as replacement volumes grow.

Factors That May Offset the Gains for NPCE

Weak Performance and Lowered Guidance: NeuroPace's third-quarter performance fell short of management's expectations, with RNS System revenues increasing just 1.4% year over year to $22.9 million. Total revenues declined 1.1% to $23.1 million. The company lowered its 2026 total revenue guidance to $91-$92 million from its previous range of $99.5-$101.5 million. Management expects fourth-quarter RNS revenue growth of approximately 5% at the midpoint, indicating that a meaningful recovery in commercial performance will take time. This near-term weakness highlights the challenges in translating physician interest and patient demand into completed procedures.

Customer Concentration and Commercial Execution Challenges: A significant portion of the third-quarter shortfall stemmed from operational disruptions at several large accounts, including staffing changes, physician availability and limited diagnostic procedure capacity. Midyear changes in sales leadership and field clinical roles also disrupted certain territories. Exiting the SEEG distribution business reduced the field team's routine operating-room engagement, affecting patient identification and referrals at some major RNS accounts. Although management believes these issues are largely transient and has begun seeing recovery, restoring procedural volumes and improving sales execution remain important challenges.

Regulatory and Adoption-Related Uncertainties: NeuroPace's anticipated market expansion into IGE and adolescent focal epilepsy remains dependent on FDA review and approval. The IGE amendment requires additional statistical analyses and supporting clinical evidence, with the company planning for a full 180-day review. The AURORA study must generate sufficient real-world evidence to support the adolescent indication submission. Adult focal epilepsy involves a lengthy six-to-nine-month patient journey from identification to implantation. These regulatory requirements and extended patient conversion timelines could delay the realization of the company's broader growth opportunities.

Estimate Trend

NeuroPace has been witnessing a stable estimate revision trend for 2026. Over the past 60 days, the Zacks Consensus Estimate for its loss per share has remained unchanged at 37 cents.

The Zacks Consensus Estimate for 2026 revenues is pegged at $96.9 million, indicating a 4.1% decrease from the year-ago reported numbers.

Key Picks

Some better-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .

Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.

Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.

Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.

West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.

WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.

Published in